Breast Cancer Clinical Trials

84 trials recruiting in Canada.

Cancer

RecruitingDrugDeviceBehavioralOlder adultsHealthy volunteers

55 trials · showing 30

Comparing Ovarian Function Suppression + with Adjuvant Chemotherapy + Ovarian for breast cancer

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Ovarian Function Suppression + Aromatase Inhibitor. Group B, the comparison group, receives Adjuvant Chemotherapy + Ovarian Function Suppression and Ovarian Function Suppression + Aromatase Inhibitor.

Sites in Montreal, Barrie and 9 more cities

  • Phase 3
  • 2 groups
  • Sites in Barrie, Kitchener and 9 more cities
  • Recruiting

Official title: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Breast Cancer · NRG Oncology

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for breast cancer.

Comparing 4 approaches for advanced breast cancer

Explore this study →

There are 4 groups in this study. Group A receives Saruparib (AZD5305) and Camizestrant. Group B, the comparison group, receives one or more of: Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole and Exemestane. Group C receives Camizestrant, together with one or more of: Abemaciclib, Ribociclib and Palbociclib. …and 1 more groups.

Sites in Montreal, Toronto and 2 more cities

  • Phase 3
  • 4 groups
  • Sites in Toronto, Greenfield Park and 2 more cities
  • Recruiting

Official title: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Advanced Breast Cancer · AstraZeneca

Comparing 3 approaches for metastatic breast cancer

Explore this study →

There are 3 groups in this study. Group A receives Phesgo and Taxane-based Chemotherapy. Group B receives Inavolisib and Phesgo, together with one or more of: Optional Endocrine Therapy of Investigator's Choice. Group C, the comparison group, receives Placebo and Phesgo, together with one or more of: Optional Endocrine Therapy of Investigator's Choice.

Sites in Montreal, Calgary and 5 more cities

  • Phase 3
  • 3 groups
  • Sites in Calgary, Moncton and 5 more cities
  • Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer · Hoffmann-La Roche

Comparing 3 approaches for triple negative breast neoplasms

Explore this study →

There are 3 groups in this study. Group A receives Sacituzumab tirumotecan, together with one or more of: Rescue Medication. Group B receives Sacituzumab tirumotecan and Pembrolizumab, together with one or more of: Rescue Medication. Group C, the comparison group, receives one or more of: Paclitaxel, Nab-paclitaxel, Gemcitabine and Carboplatin.

Sites in Montreal, Toronto and 5 more cities

  • Phase 3
  • 3 groups
  • Sites in Edmonton, Oshawa and 5 more cities
  • Recruiting

Official title: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms · Merck Sharp & Dohme LLC

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Breast Cancer trials near you.

Breast Cancer
Want matched now instead? →
← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.